Burgess B. Freeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burgess B. Freeman has a total of 307 co-authors. Here are the top co-authors by number of shared publications:
- Charles G. Mullighan
St Jude Children's Research Hospital, Memphis, Tennessee, United States
75 shared publications - Shondra M. Pruett-Miller
Department of Cell and Molecular Biology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
75 shared publications - Elena Varotto
Department of Oncology, St. Jude Children’s Research Hospital, Memphis, USA
74 shared publications - Ilaria Iacobucci
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
74 shared publications - Jun J. Yang
Department of Pharmacy and Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
74 shared publications - Kristine R. Crews
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, USA
74 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
A multi-national consortium of γδ T-ALL study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
A multi-national consortium of γδ T-ALL study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) between PF382-STAG2KO and PF382-WT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Comparison of clinical characteristics and outcomes between gamma delta T-ALL and non-gamma delta T-ALL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The genomic features of “Chromosome gains” and “TLX3” subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The genomic features of “Chromosome gains” and “TLX3” subtypes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The gene expression profiles of γδ T-ALL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
The gene expression profiles of γδ T-ALL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Compounds used in single-dose (10uM) drug screening.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Compounds used in single-dose (10uM) drug screening.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differentially expressed genes (adjusted P <0.01 ) in STAG2/LMO2 subtype compared to other T-ALL cases.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S19 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differential peaks of H3K27ac and differentially expressed genes in gene-edited PF382 model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S19 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Differential peaks of H3K27ac and differentially expressed genes in gene-edited PF382 model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Detected structural variants by whole genome sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Detected structural variants by whole genome sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Common differentially expressed genes (adjusted P <0.01 ) in PF382-STAG2KO v. PF382-WT model and primary samples with STAG2/LMO2 v. other subtypes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S18 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk
Common differentially expressed genes (adjusted P <0.01 ) in PF382-STAG2KO v. PF382-WT model and primary samples with STAG2/LMO2 v. other subtypes.